Promega Contributing to the prevention, healing and more. Founded in 1978, which began with the production of enzymes for research, has evolved into a catalog of over 2,000 products for a wide range of applications, including basic research, drug discovery, forensics, paternity testing and diagnosis clinician.

Discovers, develops, manufactures, and markets animal products and develops vaccines for animal and human health

Berg is a Swiss private company located in Berg, with subsidiaries in Spain, providing investment services.

The USC Incubator accelerates the development of USC’s top student and alumni entrepreneurs through experiential education, mentorship and community. The USC Incubator, supported by the Greif Center for Entrepreneurial Studies at USC’s Marshall School takes founders from feasibility and development work, on to customers, a tested business model, getting distribution, building a team, bootstrapping and investment preparation. They also provide access to other supporting resources, such as legal and financial assistance.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Hitachi Chemical co., ltd. is a chemical manufacturer engaged in a wide range of areas, including semiconductor and display-related materials, printed wiring boards, copper clad laminates, photosensitive dry films, functional polymeric materials, adhesive films, carbon products, ceramics and automotive related products. Hitachi Chemical co., ltd. is a manufacturer of semiconductor- and display-related materials, printed wiring boards, copper clad laminates, photosensitive dry films, functional polymeric materials, adhesive films, carbon products, ceramics and automotive related products.

Zaporizhzhia State Medical University (ZSMU) is a medical university in the small city of Zaporizhzhia, Ukraine.

Dako Denmark A/S designs and manufactures cancer diagnostic systems. It produces reagents, antibodies, instruments, and software solutions to make diagnoses and determine treatments for patients suffering from cancer. The firm's product areas encompass Immunohistochemistry, pharmacoDiagnostics, molecular pathology, Hematoxylin and Eosin stain, special stains, flow Cytometry, and specific proteins. The company was founded by Niels Harboe in 1966 and is headquartered in Glostrup, Denmark.

Beijing Yimiao Medical Technology Co., Ltd., established on 2018-01-05, Business scope includes medical technology development,to promote,transfer,consult,Serve;software development;Medical Research and Experimental Development;manufacturing biological products.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Shanghai Anyi Biotechnology Co., Ltd., established on 2019-04-11, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Instrument sales;Experimental analysis instrument sales;Sales of daily glass products;Sales of labor protection products;Hardware retail;Sales of power electronic components;Wholesale of computer software, hardware and auxiliary equipment;Office Supplies Sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services.

Ningxia Wanhou Biotechnology Co., Ltd., established on 2018-04-08, The scope of business includes engaging in technology development in the professional field of biotechnology,technology transfer,technical consulting,Technical Services;fungicide,preservative,antifungal agent,Antibacterial agents,Anti-algae agent,Research and Development of Disinfectants,Production,Sales,Serve;Research and development of functional plastic masterbatch,Production,Sales,Serve;and business information consultation;Chemical raw materials,Chemical Products(Free of Hazardous Chemicals),Equipment,Sales of mechanical parts.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

NeuroBo Pharmaceuticals is addressing unmet needs in patients with diabetic neuropathy and Alzheimer’s disease. Their Phase III-ready drug, NB-01, is based on natural sources and has shown successful Phase II results with excellent efficacy and safety in diabetic neuropathic pain (DNP) and they have strong preclinical data in both neuropathic pain and diabetes models showing a mode of action of NB-01 on nerve growth factor (NGF) release for nerve stabilization and regeneration. 40 to 50 percent of patients with diabetic peripheral neuropathy have some form of neuropathic pain and while existing drugs alleviate pain symptoms, they do not address the underlying disease. These current therapies also have a range of adverse effects, and only about 50 percent of patients respond positively. Additionally, the current therapies on the market were all initially approved for other disease states such as depression and fibromyalgia. NB-02, their lead Alzheimer’s drug, is in IND-enabling stage and has been extensively characterized in rodent models for mechanisms impacting Alzheimer’s disease (inhibition of AChE, pTau, amyloid-β, and stimulation of NGF for nerve growth. An aging population has resulted in an increase in the prevalence of Alzheimer’s disease, and the disease is a significant healthcare burden. Today, there are four approved drugs that manage the symptoms of Alzheimer’s disease, yet none of these four address disease modification.